BRPI0414254A - composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação - Google Patents

composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação

Info

Publication number
BRPI0414254A
BRPI0414254A BRPI0414254-3A BRPI0414254A BRPI0414254A BR PI0414254 A BRPI0414254 A BR PI0414254A BR PI0414254 A BRPI0414254 A BR PI0414254A BR PI0414254 A BRPI0414254 A BR PI0414254A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
disease
formulation
treating
manufacturing
Prior art date
Application number
BRPI0414254-3A
Other languages
English (en)
Inventor
Francisco J Alvarez
Glean Gary Lawrence
Hung-Ren H Lin
Tzuchi R Ju
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to BR122018013029-6A priority Critical patent/BR122018013029B1/pt
Publication of BRPI0414254A publication Critical patent/BRPI0414254A/pt
Publication of BRPI0414254B1 publication Critical patent/BRPI0414254B1/pt
Publication of BRPI0414254B8 publication Critical patent/BRPI0414254B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA FABRICAR UMA COMPOSIçãO FARMACêUTICA, PARA O TRATAMENTO DE PELO MENOS UMA DOENçA E PARA CONTROLAR A TAXA DE DISSOLUçãO DE UMA FORMULAçãO". A presente invenção diz respeito a uma composição farmacêutica que compreende uma quantidade terapeuticamente eficaz de um composto ativo receptor de cálcio e pelo menos um excipiente farmaceuticamente aceitável, em que a composição tem um perfil de dissolução controlado. A presente invenção ainda diz respeito a um método para fabricar a composição farmacêutica, bem como um método de tratar uma doença usando a composição farmacêutica.
BRPI0414254A 2003-09-12 2004-09-10 composição farmacêutica compreendendo hcl de cinacalceto BRPI0414254B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018013029-6A BR122018013029B1 (pt) 2003-09-12 2004-09-10 Método para fabricar uma composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
US60/502,219 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Publications (3)

Publication Number Publication Date
BRPI0414254A true BRPI0414254A (pt) 2006-11-07
BRPI0414254B1 BRPI0414254B1 (pt) 2021-03-02
BRPI0414254B8 BRPI0414254B8 (pt) 2021-05-25

Family

ID=34434844

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0414254A BRPI0414254B8 (pt) 2003-09-12 2004-09-10 composição farmacêutica compreendendo hcl de cinacalceto
BR122018013029-6A BR122018013029B1 (pt) 2003-09-12 2004-09-10 Método para fabricar uma composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018013029-6A BR122018013029B1 (pt) 2003-09-12 2004-09-10 Método para fabricar uma composição farmacêutica

Country Status (30)

Country Link
US (7) US7829595B2 (pt)
EP (8) EP1663182B2 (pt)
JP (3) JP5026077B2 (pt)
KR (1) KR101332058B1 (pt)
CN (1) CN1946382B (pt)
AR (1) AR045637A1 (pt)
AU (1) AU2004279318C1 (pt)
BR (2) BRPI0414254B8 (pt)
CA (1) CA2536487C (pt)
CY (5) CY1119609T1 (pt)
DE (1) DE19164145T1 (pt)
DK (6) DK3395340T3 (pt)
EA (1) EA013425B1 (pt)
ES (7) ES2737348T3 (pt)
HR (1) HRP20130114T4 (pt)
HU (5) HUE043958T2 (pt)
IL (1) IL173737A (pt)
IS (1) IS3027B (pt)
MX (1) MXPA06002616A (pt)
MY (1) MY142046A (pt)
NO (1) NO335739B1 (pt)
NZ (1) NZ545498A (pt)
PL (6) PL3260117T3 (pt)
PT (6) PT3395338T (pt)
SG (1) SG146608A1 (pt)
SI (6) SI3395339T1 (pt)
TR (4) TR201910447T4 (pt)
TW (1) TWI344363B (pt)
WO (1) WO2005034928A1 (pt)
ZA (1) ZA200602710B (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663182B2 (en) * 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
KR20070116286A (ko) * 2005-05-16 2007-12-07 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염산염의 제조 방법
EP1883625A2 (en) * 2005-05-23 2008-02-06 Teva Pharmaceutical Industries Ltd Amorphous cinacalcet hydrochloride and preparation thereof
ATE445587T1 (de) * 2005-05-23 2009-10-15 Teva Pharma Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
JP4733120B2 (ja) 2005-05-26 2011-07-27 大日本住友製薬株式会社 医薬品組成物
WO2007027548A2 (en) * 2005-09-02 2007-03-08 Amgen Inc. Methods of modulating intestinal fluid balance
EP1828098A1 (en) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
CA2645494C (en) * 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
WO2007127449A1 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
US7449603B2 (en) * 2006-04-27 2008-11-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
PT3357496T (pt) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
WO2008000422A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag Amorphous form of cinacalcet
EP1945184A2 (en) * 2006-09-01 2008-07-23 Teva Pharmaceutical Industries Ltd. Solid composites of a calicum receptor-active compound
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
EP1968932A1 (en) * 2006-11-20 2008-09-17 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
CN101668532B (zh) 2007-04-25 2014-08-20 赛特克罗公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
KR20190141269A (ko) 2007-04-25 2019-12-23 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
EP2170805B1 (en) 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
US20090275780A1 (en) * 2008-05-05 2009-11-05 Medichem, S.A. Process for controlling the particle size of a 3-(trifluoromethyl)phenyl]-1-aminopropane derivative
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20120009258A1 (en) * 2008-09-25 2012-01-12 Ratiopharm Gmbh Compacted cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
EP2435400A2 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
HUE049344T2 (hu) * 2010-11-23 2020-09-28 Amgen Inc Gyermekgyógyászati készítmény
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
EP2643298A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
CN104379159A (zh) 2011-12-19 2015-02-25 安姆根公司 变体激活素受体多肽,单独或与化疗结合,及其用途
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
DK2730279T3 (en) * 2012-11-09 2015-10-26 K H S Pharma Holding Gmbh CINACALCETFORMULERINGER immediate release
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
AU2013366640B2 (en) * 2012-12-21 2018-09-06 Synthon B.V. Tablet composition comprising cinacalcet hydrochloride
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2014207691A1 (en) 2013-06-26 2014-12-31 Jubilant Life Sciences Limited Disintegrant free composition of cinacalcet
WO2015136329A1 (en) * 2014-03-14 2015-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
EP4596045A3 (en) 2016-03-28 2025-10-15 EirGen Pharma Ltd. Methods of vitamin d treatment
CN109152787A (zh) 2016-03-31 2019-01-04 英特塞普特医药品公司 具有优越的溶出性的口服制剂
WO2019034981A1 (en) * 2017-08-16 2019-02-21 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING CINACALCET CHLORHYDRATE AND ONE OR MORE BINDERS
US20210030671A1 (en) 2018-03-30 2021-02-04 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
AU2021226416A1 (en) * 2020-02-29 2022-09-15 Zevra Therapeutics, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IL88150A0 (en) 1987-11-02 1989-06-30 Merck & Co Inc Pharmaceutical tablet compositions containing phthalizine acetic acid compounds
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
KR900701255A (ko) 1988-11-30 1990-12-01 스테이너 브이.캔스타드 서방성 딜티아젬 제제
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2256370T3 (es) 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DK0724561T3 (da) 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DE69333527T2 (de) 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
UA41909C2 (uk) * 1994-07-22 2001-10-15 Елі Ліллі Енд Компані Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
CN1147459C (zh) 1994-10-21 2004-04-28 Nps药物有限公司 钙受体活性化合物
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
ATE430123T1 (de) 1996-05-01 2009-05-15 Nps Pharma Inc Inorganische am ionen-rezeptor aktive verbindungen
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
ES2364179T3 (es) 1996-07-08 2011-08-26 Kyowa Hakko Kirin Co., Ltd. Compuestos con actividad receptora de calcio.
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
ATE219658T1 (de) 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
CA2347092A1 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
PL348907A1 (en) * 1998-11-23 2002-06-17 Monsanto Co Highly concentrated aqueous glyphosate compositions
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
AU2001288102A1 (en) 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (pt) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
DE60220049T2 (de) 2001-06-22 2007-08-30 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
AU2003238670A1 (en) 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
WO2004030669A1 (en) 2002-09-30 2004-04-15 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
EP1663182B2 (en) 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
CA2717906C (en) 2008-03-11 2022-07-05 Jamu Alford System and method for magnetic resonance imaging

Also Published As

Publication number Publication date
PL3395340T3 (pl) 2019-10-31
ES2401769T3 (es) 2013-04-24
HRP20130114T1 (xx) 2013-03-31
TR201910180T4 (tr) 2019-07-22
JP2015007089A (ja) 2015-01-15
NZ545498A (en) 2010-04-30
CY1121814T1 (el) 2020-07-31
US20200222340A1 (en) 2020-07-16
JP5026077B2 (ja) 2012-09-12
HUE044822T2 (hu) 2019-11-28
SG146608A1 (en) 2008-10-30
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
EP1663182A1 (en) 2006-06-07
KR101332058B1 (ko) 2013-11-22
MXPA06002616A (es) 2006-06-05
CA2536487A1 (en) 2005-04-21
DK2821067T3 (en) 2017-12-04
TWI344363B (en) 2011-07-01
HUE035596T2 (en) 2018-05-28
PT1663182E (pt) 2013-03-14
NO335739B1 (no) 2015-02-02
AU2004279318A1 (en) 2005-04-21
CY1121812T1 (el) 2020-07-31
EP3260117B1 (en) 2019-04-17
WO2005034928A1 (en) 2005-04-21
CY1121820T1 (el) 2020-07-31
ES2401769T5 (es) 2020-07-01
TR201909267T4 (tr) 2019-07-22
TW200518743A (en) 2005-06-16
CY1119609T1 (el) 2018-04-04
JP5940120B2 (ja) 2016-06-29
DK3395340T3 (da) 2019-07-15
PL3395338T3 (pl) 2019-10-31
BR122018013029B1 (pt) 2022-04-12
DE19164145T1 (de) 2021-04-29
TR201910177T4 (tr) 2019-08-21
US20160338975A1 (en) 2016-11-24
SI1663182T1 (sl) 2013-05-31
US20110136915A1 (en) 2011-06-09
DK1663182T3 (da) 2013-04-15
CA2536487C (en) 2011-10-25
PL1663182T3 (pl) 2013-06-28
TR201910447T4 (tr) 2019-08-21
SI2821067T1 (en) 2018-03-30
IS3027B (is) 2021-03-15
ES2812198T1 (es) 2021-03-16
HUE045411T2 (hu) 2019-12-30
IL173737A (en) 2012-04-30
EA013425B1 (ru) 2010-04-30
EP3260117A1 (en) 2017-12-27
CN1946382A (zh) 2007-04-11
US20210052518A1 (en) 2021-02-25
PT3395340T (pt) 2019-07-15
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
EP3395339B1 (en) 2019-04-17
DK3260117T3 (da) 2019-07-01
DK3395339T3 (da) 2019-07-22
EP3260117B8 (en) 2019-11-27
BRPI0414254B8 (pt) 2021-05-25
PL2821067T3 (pl) 2018-02-28
SI3395340T1 (sl) 2019-08-30
SI1663182T2 (sl) 2020-02-28
MY142046A (en) 2010-08-30
EP3395339B8 (en) 2019-12-11
PT3395338T (pt) 2019-07-23
AU2004279318B2 (en) 2010-02-25
EP3395340B8 (en) 2019-12-11
PL1663182T5 (pl) 2020-07-27
ZA200602710B (en) 2007-04-25
EA200600566A1 (ru) 2006-08-25
US20190117592A1 (en) 2019-04-25
PL3395339T3 (pl) 2019-09-30
KR20070017460A (ko) 2007-02-12
SI3395339T1 (sl) 2019-08-30
EP3395338A1 (en) 2018-10-31
DK3395338T3 (da) 2019-07-22
EP3578175B1 (en) 2022-11-30
JP2012197280A (ja) 2012-10-18
CN1946382B (zh) 2010-12-08
SI3260117T1 (sl) 2019-08-30
EP2316442A1 (en) 2011-05-04
EP3395338B1 (en) 2019-05-01
US9375405B2 (en) 2016-06-28
US20050147669A1 (en) 2005-07-07
AU2004279318C1 (en) 2020-06-25
CY1122259T1 (el) 2020-11-25
PT3395339T (pt) 2019-07-15
EP1663182B2 (en) 2019-11-20
AR045637A1 (es) 2005-11-02
NO20061640L (no) 2006-06-12
EP3395340A1 (en) 2018-10-31
DK1663182T4 (da) 2020-02-17
ES2735216T3 (es) 2019-12-17
IL173737A0 (en) 2006-07-05
JP2007505108A (ja) 2007-03-08
SI3395338T1 (sl) 2019-08-30
ES2655435T3 (es) 2018-02-20
HUE044279T2 (hu) 2019-10-28
EP2821067A1 (en) 2015-01-07
ES2734057T3 (es) 2019-12-04
EP3395340B1 (en) 2019-04-17
US7829595B2 (en) 2010-11-09
ES2737348T3 (es) 2020-01-13
PL3260117T3 (pl) 2019-10-31
BRPI0414254B1 (pt) 2021-03-02
PT2821067T (pt) 2017-12-01
EP2821067B1 (en) 2017-10-25
US20180243238A1 (en) 2018-08-30
JP5849015B2 (ja) 2016-01-27
PT3260117T (pt) 2019-07-04
EP3395339A1 (en) 2018-10-31
IS8324A (is) 2006-02-23
ES2735226T3 (es) 2019-12-17

Similar Documents

Publication Publication Date Title
BRPI0414254A (pt) composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação
BRPI0508561A (pt) 3-'4-heterociclil-1,2,3-triazol-1-il-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crÈnicas
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
PT2172450E (pt) Novo derivado sulfonamida de ácido malónico e sua utilização farmacêutica
IS6719A (is) Aðferð til verkjadeyfingar
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
RU2007138263A (ru) Противовоспалительные соединения
PH12022552807A1 (en) Novel compound [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate 4-methyl-2h-chromen-2-on-7-yl sulphate and use thereof
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
MA27157A1 (fr) Methode de traitement d'affections osseuses.
CY1113703T1 (el) Ταχειας διαλυσης φαρμακοτεχνικη μορφη της σινακαλσετης hci
WO2005113011A3 (en) Prodrugs of ion channel modulating compounds and uses thereof
MY167609A (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
WO2008016661A3 (en) Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
RU2007138266A (ru) Комбинация ингибитора стероидсульфатазы и аскомицина
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15N Others concerning applications: notification of judicial decision

Free format text: INPI-52400.210725/2017-51 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO 0214721-08.2017.4.02.5101 AUTOR: AMGEN INC. REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: EMENTA - MANDADO DE SEGURANCA IMPETRADO COM A FINALIDADE DE EXIGIR QUE A AUTORIDADE IMPETRADA INICIE, NO PRAZO DE 60 (SESSENTA) DIAS, O EXAME DE MERITO DA PATENTE PI 0414254-3, COM DEPOSITO EFETUADO VIA PCT HA MAIS DE MAIS DE TREZE ANOS.RECONHECIMENTO DE DEMORA EXCESSIVA E DESARRAZOADA DO INPI PARA PRATICAR O ATO, CARACTERIZANDO VIOLACAO DOS ARTIGOS 5O, XXXIII, DA CF, E 48 E 49, DA LEI 9.784/99.APELACAO DESPROVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15N Others concerning applications: notification of judicial decision

Free format text: INPI-52400.210725/2017-51 SECAO: 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0214721-08.2017.4.02.5101 APELANTE: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI APELADO: AMGEN INC DECISAO: O TRANSITO EM JULGADO DO ACORDAO CONFIRMANDO SENTENCA DESFAVORAVEL AO INPI.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed